Correction: Brentuximab vedotin plus chemotherapy for the treatment of front-line systemic anaplastic large cell lymphoma: subgroup analysis of the ECHELON-2 study at 5 years’ follow-up

Following the publication of this article, the authors noted the following sentence could be misinterpreted: ‘In patients with ALK– sALCL, the estimated 5-year PFS rate (95% CI) was 56.8% (40.5–70.2%) and 56.0% (39.3–69.7%) in the A + CHP and CHOP arms, respectively’. This sentence is in fact about patients with ALK– sALCL who achieved a complete response (CR), and while the sentence appears in the context of a paragraph discussing patients with a CR, the following correction has been made to avoid confusion: ‘In patients with ALK– sALCL who achieved CR, the estimated 5-year PFS rate (95% CI) was 56.8% (40.5–70.2%) and 56.0% (39.3–69.7%) in the A + CHP and CHOP arms, respectively’. Data showing 5-year PFS in patients with ALK– disease, regardless of response, appear in Figure 1.